Introduction {#sec1}
============

Hepatocellular carcinoma (HCC) is the sixth most common tumour and the third leading cause of cancer mortality globally \[[@cit0001]--[@cit0004]\]. Surgical resection and liver transplantation combined with systemic therapy is considered an effective treatment for HCC, but the 5-year survival rate is still below 12% \[[@cit0005], [@cit0006]\]. Therefore, it is urgent to fully understand the pathogenesis of HCC and explore effective biomarkers that can predict the progression and prognosis of patients with HCC after clinical treatments, which may provide doctors a novel and effective treatment strategy and improve the survival rate of HCC patients.

GP73, a type-II Golgi transmembrane glycoprotein, was first reported in 2000 \[[@cit0007]\]. Many studies have shown that GP73 is highly expressed in HCC but poorly or not expressed in normal adult tissue \[[@cit0008]\]. A number of previous publications suggested that GP73 can be regarded as a reliable diagnostic biomarker \[[@cit0009]--[@cit0011]\] and that its diagnostic sensitivity and specificity may be superior to those of α-fetoprotein (AFP) \[[@cit0012]--[@cit0014]\]. Further research showed that GP73 expression was positively associated with HCC invasion and metastasis \[[@cit0015]--[@cit0017]\]. GP73 may be a new and independent biomarker for evaluating the prognosis of HCC patients. However, the results of different articles regarding GP73 in predicting the prognosis in HCC are still controversial. Hou *et al.* \[[@cit0018]\] conducted a meta-analysis previously to assess the relationship of GP73 expression and patients' prognostic statuses after surgery. However, Xu Hou's study evaluating the prognostic value of GP73 in patients with HCC included only 5 studies. The most recently published studies that explore the correlation between GP73 and prognostic value in HCC were not incorporated \[[@cit0015], [@cit0017], [@cit0019], [@cit0020]\], restricting the statistical power of the meta-analysis. Therefore, we performed a meta-analysis to comprehensively and systematically evaluate the association between GP73 expression and HCC prognosis.

In this meta-analysis, we aimed to evaluate the correlation of GP73 expression with OS and DFS in HCC with the available data extracted and pooled from included studies. In addition, we analysed the correlation between GP73 expression and clinicopathological parameters (tumour stage and grade).

Material and methods {#sec2}
====================

Literature search {#sec2.1}
-----------------

PubMed, EMBASE, Cochrane Library and the Chinese Biomedical Literature Database were searched systematically in March 2018 to identify eligible studies. The search keywords were ("Golgi protein 73" \[All Fields\] OR "GP73" \[All Fields\]) AND ("hepatocellular carcinoma" \[All Fields\] OR "HCC" \[All Fields\]) AND ("prognosis" \[All Fields\] OR "prognostic" \[All Fields\]).

Eligible studies had to meet the following criteria: (1) hazard ratio (HR) and 95% confidence interval (CI) for OS and DFS were provided or could be calculated from available information; (2) the sample size was more than 20; (3) the level of GP73 was measured by immunohistochemistry; and (4) the study was published in English or Chinese.

Data extraction and quality evaluation {#sec2.2}
--------------------------------------

Data from each article were extracted independently by two investigators (Jian Zhang and Manka Zhang) based on the standard forms. All authors of the study discussed the differences if the two investigators had a disagreement. The following information was recorded from each study: first author, sample size, follow-up periods, method of clinical treatment, publication year, patients' basic features, cut-out level, vascular invasion, hepatic cirrhosis, the differentiation and stage of tumour, HR or OR and its 95% CI. If the studies included in the meta-analysis did not provide HRs and their 95% CIs directly, the data were extrapolated indirectly by methods introduced by Tierney *et al.* \[[@cit0021]\] or a Kaplan-Meier survival curve or the author was contacted to obtain the raw data.

A quality assessment was also evaluated by two independent investigators who applied the standard Newcastle-Ottawa scale, which included 3 factors: Selection, Comparability, and Outcome categories. Numbers 0 and 9 (labelled with stars) represent the lowest and highest quality, respectively. Those with 6 or more stars were graded as high-quality studies.

Statistical analysis {#sec2.3}
--------------------

In this meta-analysis, Review Manager 5 and IBM SPSS Statistics 20 were applied to conduct all statistical analyses (available from <http://www.cochrane.org/>). Hazard ratios (HR) and 95% confidence intervals (95% CI) were determined to assess the associations of GP73 expression with overall survival (OS) and disease-free survival (DFS). Odds ratios (ORs) with 95% CIs were conducted to evaluate the relationship between GP73 and clinicopathological features for HCC. The *I^2^* statistic was adopted to evaluate the extent of heterogeneity. If the *I^2^* value exceeded 50%, then significant heterogeneity was present, and the random effects model was adopted \[[@cit0022]\]. Otherwise, a fixed-effect model was adopted. Publication bias was checked by Begg funnel plots. Statistical significance was set at *p* \< 0.05.

Results {#sec3}
=======

Study selection and characteristics {#sec3.1}
-----------------------------------

A total of 306 studies that examined the correlation of GP73 and HCC were identified by using the above keywords. Thirty-five studies were excluded because they were case reports, reviews, letters to the editor, and duplications. After the full text was reviewed and evaluated, 46 studies were removed because of a lack of relevant topic or sufficient survival data. Finally, nine studies with 1292 patients met the requirements and were used to evaluate the prognostic value of GP73 ([Figure 1](#f0001){ref-type="fig"}) \[[@cit0015], [@cit0017], [@cit0019], [@cit0020], [@cit0023]--[@cit0027]\]. All studies included in the meta-analysis used immunohistochemistry to detect GP73 expression levels. OS can be extracted from all articles, while DFS was presented in 3 studies. The quality assessment of articles, as evaluated by the Newcastle-Ottawa scale, ranged from 5 to 8 (with a mean of 6.4). The clinicopathological characteristics of the nine studies are summarized in [Table I](#t0001){ref-type="table"}.

###### 

Characteristics of studies included

  Author           Year   Country   Number of patients   Duration of follow-up \[months\]   Treatment     Antibody type       Detection method   Cut-off value   Study quality   OS      DFS                     
  ---------------- ------ --------- -------------------- ---------------------------------- ------------- ------------------- ------------------ --------------- --------------- ------- --------------- ------- --------------
  Jiang *et al.*   2016   China     90                   80                                 Hepatectomy   Goat monoclonal     IHC                25%             8               1.7     1.06--2.95      NA      NA
  Chen *et al.*    2013   China     193                  51                                 Hepatectomy   Monoclonal          IHC                Score \> 150    6               1.696   1.16 -- 2.479   1.765   1.1--2.026
  Ye *et al.*      2016   China     284                  60                                 Hepatectomy   Monoclonal          IHC                Score \> 2      7               1.846   1.281--2.660    1.772   1.039--3.023
  Bao *et al.*     2013   China     75                   20                                 Hepatectomy   Rabbit monoclonal   IHC                20%             6               3.7     1.8--7.61       NA      NA
  Sun *et al.*     2011   China     36                   18.5                               Hepatectomy   Goat monoclonal     IHC                NA              6               1.11    0.23--5.26      NA      NA
  Shan *et al.*    2013   China     60                   36                                 Hepatectomy   Goat monoclonal     IHC                NA              5               0.338   0.132--0.855    0.485   0.242--0.972
  Sai *et al.*     2015   China     157                  60                                 Hepatectomy   Monoclonal          IHC                25%             7               1.66    1.09--2.53      NA      NA
  Dai *et al.*     2015   China     217                  84                                 Hepatectomy   NA                  IHC                NA              7               2.51    1.45--4.34      NA      NA
  Li *et al.*      2015   China     180                  36                                 Hepatectomy   NA                  IHC                25%             6               2.01    1.26--3.22      NA      NA

OS -- overall survival, DFS -- disease-free survival, NA -- not available, IHC -- immunohistochemistry, CI -- confidence interval, HR -- hazard ratio.

![Flow diagram of the study selection process](AMS-16-5-36136-g001){#f0001}

GP73 expression and OS in HCC {#sec3.2}
-----------------------------

Nine articles reported the association of GP73 expression and OS in HCC \[[@cit0015], [@cit0017], [@cit0019], [@cit0020], [@cit0023]--[@cit0017]\]. The pooled data demonstrated a significant correlation between high GP73 expression and poor OS (HR = 1.76, 95% CI: 1.35--2.31, *p* \< 0.0001; [Figure 2](#f0002){ref-type="fig"}). A random effects model was adopted in this meta-analysis as there was obvious heterogeneity in the data (*I*^2^ = 56%, *p* = 0.02).

![Association between GP73 overexpression and overall survival of HCC](AMS-16-5-36136-g002){#f0002}

GP73 expression and DFS in HCC {#sec3.3}
------------------------------

The association of GP73 with DFS was presented in three studies \[[@cit0020], [@cit0024], [@cit0025]\]. The overall meta-analysis showed no significant association between elevated GP73 levels and DFS (HR = 1.19, 95% CI: 0.57--2.52, *p* = 0.64; [Figure 3](#f0003){ref-type="fig"}). Since heterogeneity is obvious in the study (*I^2^* = 81%, *p* = 0.005), the random effects model was applied to calculate the pooled HR.

![Association between GP73 overexpression and disease-free survival of HCC](AMS-16-5-36136-g003){#f0003}

GP73 expression and clinicopathological characteristics of HCC {#sec3.4}
--------------------------------------------------------------

Several articles assessed the correlation of high GP73 expression with HBV or HCV infection, tumour size, histological grade, vascular invasion, liver cirrhosis, tumour number, and tumour stage. The result indicated that high GP73 expression was significantly correlated with higher tumour grade (OR = 3.72, 95% CI: 1.26--11.02, *p* = 0.02) and later tumour stage (OR = 3.43, 95% CI: 1.74--6.73, *p* = 0.0003) ([Table II](#t0002){ref-type="table"}).

###### 

Association between high GP73 expression and clinicopathological features

  Parameter                               *N* of studies   *N* of patients   Effect model   OR (95% CI)          *P*-value   Heterogeneity test   
  --------------------------------------- ---------------- ----------------- -------------- -------------------- ----------- -------------------- ----------
  HBV(+/--)                               5                829               Fixed          0.95 (0.65--1.40)    0.80        0                    0.52
  HCV(+/--)                               2                253               Fixed          0.87 (0.48--1.57)    0.64        0                    0.84
  Tumour size (≥ 5 cm/\< 5 cm)            5                934               Fixed          0.99 (0.63--1.58)    0.97        0                    0.66
  Histological grade (G2--3/G1)           5                816               Random         3.72 (1.26--11.02)   0.02        90                   \< 0.001
  Vascular invasion (positive/negative)   5                1009              Random         1.29 (0.58--2.89)    0.82        83                   \< 0.001
  Liver cirrhosis                         6                1091              Random         1.28 (0.75--2.19)    0.36        78                   \< 0.001
  Tumour number (multiple/single)         5                874               Random         1.68(0.51--5.54)     0.4         86                   \< 0.001
  Stage (III--IV/I--II)                   6                986               Random         3.43 (1. 74--6.73)   0.0003      67                   0.01

CI -- confidence interval, GP73 -- Golgi protein 73, HBV -- hepatitis B virus, HCV -- hepatitis C virus, N -- number, OR -- odds ratio.

Subgroup analysis {#sec3.5}
-----------------

We also performed subgroup analyses to investigate the association of GP73 expression and OS according to sample size and follow-up period ([Table III](#t0003){ref-type="table"}). In the results of the subgroup analysis of the studies by sample size, the HR obtained from studies with more than 90 cases was 1.84 (95% CI: 1.54--2.19, *p* \< 0.001). However, the pooled HR was 1.47 (95% CI: 0.85--2.51, *p* = 0.17) in the studies with fewer than 90 cases. Similarly, when the studies were analysed based on the follow-up period, the results showed that there was a significantly poorer prognosis among studies with longer follow-up periods (≥ 60 months) (HR = 1.85, 95% CI: 1.49--2.30, *p* \< 0.001). In the combined data from articles with a shorter follow-up period (\< 60 months), there was no significant correlation between high GP73 expression and OS (HR = 1.51, 95% CI: 0. 83--2.78, *p* = 0.18).

###### 

Subgroup analyses for effect of GP73 on HCC overall survival

  Parameter                           *N* of studies   Effect model   HR (95% CI)         *P*-value   Heterogeneity test   
  ----------------------------------- ---------------- -------------- ------------------- ----------- -------------------- ----------
  Overall                             9                Random         1.61 (1.15--2.27)   0.006       63                   0.01
  Sample size:                                                                                                             
   \< 90                              3                Random         1.47 (0.85--2.51)   0.17        87                   \< 0.001
   ≥ 90                               6                Fixed          1.84 (1.54--2.19)   \< 0.001    0                    0.86
  Duration of follow-up \[months\]:                                                                                        
   \< 60                              5                Random         1.51 (0.83--2.78)   0.18        76                   0.002
   ≥ 60                               4                Fixed          1.85 (1.49--2.30)   \< 0.001    0                    0.65

CI -- confidence interval, GP73 -- Golgi protein 73, HCC -- hepatocellular carcinoma, HR -- hazard ratio, N -- number.

Publication bias {#sec3.6}
----------------

The function of publication bias analysis is to assess the reliability of the meta-analysis results, especially those with statistical significance \[[@cit0028]\]. The Begg funnel plot method was applied to test publication bias in this meta-analysis. We observed no publication bias for the outcomes of OS, with no asymmetry observed in the funnel plot ([Figure 4](#f0004){ref-type="fig"}).

![Funnel plot for assessing publication bias in OS](AMS-16-5-36136-g004){#f0004}

Discussion {#sec4}
==========

The HCC, a malignant tumour, accounts for nearly half of all cancer cases in China. Due to the high rate of recurrence and metastasis, patients present poor prognosis after resection \[[@cit0022], [@cit0029]\]. It is urgent to discover molecular markers that can predict the recurrence and metastasis of HCC. The most recent studies showed that GP73 expression was associated with invasion and metastasis in HCC \[[@cit0015]--[@cit0017]\]. Nevertheless, the conclusions from previous studies were inconsistent. Therefore, it is appropriate to conduct a meta-analysis to systematically evaluate the association of GP73 expression and HCC prognosis.

In the present study, 9 studies were included in the meta-analysis. The number of studies included in the meta-analysis was nearly double that in Hou's study. Therefore, the results from the meta-analysis are more comprehensive and reliable. We first evaluated the relationship of high GP73 expression and survival outcomes. The combined data suggested that overexpression of GP73 was associated with poorer OS for patients with HCC (*p* \< 0.0001). Patients with overexpression of GP73 were vulnerable to shorter OS than those with low GP73 expression. Furthermore, combined HR for OS was lower than that in the Hou *et al*. meta-analysis. The main reason is that more studies were included in this meta-analysis than were included in the Hou *et al.* study, which may have produced more reliable and powerful statistics. However, the pooled HR for DFS was not significant. The reasons may be as follows: first, only three of the seven articles included in the meta-analysis demonstrated a correlation between high GP73 expression and DFS. Further studies are required to better test the results. Second, patients included in the meta-analysis all originated from China, which increases regional limitations. Therefore, the DFS outcomes need to be verified by collecting more data from more regions in prospective studies. Furthermore, we also proved that overexpression of GP73 was tightly associated with higher tumour grade and later tumour stage. The results were in accord with those from studies by Riener *et al.* \[[@cit0030]\] and Shimada *et al.* \[[@cit0031]\], which showed that these clinicopathological features are highly correlated with the aggression and metastasis of HCC.

Heterogeneity is obvious in the meta-analysis for OS and DFS. Stratified subgroup analyses were applied to decrease the heterogeneity. When we divided all the literature into two subgroups according to sample size, a significant correlation of GP73 overexpression with poorer OS was presented for studies with more than 90 cases, while no association was found in the studies with fewer than 90 cases. Therefore, more studies are required to determine the reliable value of GP73 for predicting OS in HCC. Similarly, a significant correlation was only observed in studies with a follow-up period ≥ 60 months, suggesting that the status of GP73 expression was more suitable for evaluating long-term outcomes in HCC.

We must acknowledge that several limitations exist in this meta-analysis. First, if the studies included in the meta-analysis did not provide HRs and their 95% CIs directly, then the data were extrapolated indirectly using the available data or Kaplan-Meier survival curve, which may result in imprecise outcomes. Second, the patients in the studies included in the meta-analysis had different ages, cut-off values, and follow-up times. Furthermore, all patients included in the meta-analysis originated from China. Third, publication bias cannot be ignored, because studies with positive results tend to be published more often than those with negative outcomes, which will exaggerate the correlation of high GP73 expression and poor prognosis.

In conclusion, despite the limitations mentioned above, the meta-analysis indicated that high GP73 expression correlated with poor prognosis in HCC. In addition, our study showed that GP73 overexpression was associated with later tumour stage and higher tumour grade in HCC, which indicated that GP73 may play a vital role in tumour invasion and progression. Furthermore, more prospective clinical trials are needed to evaluate the correlation of GP73 expression with prognosis in HCC.
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